CN101780142B - Leukogenic medicament containing lithium carbonate - Google Patents
Leukogenic medicament containing lithium carbonate Download PDFInfo
- Publication number
- CN101780142B CN101780142B CN2010101279945A CN201010127994A CN101780142B CN 101780142 B CN101780142 B CN 101780142B CN 2010101279945 A CN2010101279945 A CN 2010101279945A CN 201010127994 A CN201010127994 A CN 201010127994A CN 101780142 B CN101780142 B CN 101780142B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine extract
- lithium carbonate
- hours
- caulis spatholobi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition containing lithium carbonate and a Chinese medicine extractive, and application thereof in preparing medicaments for promoting the leukocyte increase.
Description
Invention field
This invention relates to the treatment disease in the blood system, the Integrative Chinese-Western medicine of leukopenia and agranulocytosis.
Background technology
Leukopenia and agranulocytosis are internal medicine blood system commonly encountered diseases, frequently-occurring disease, and its pathogenic factor can or infect and other disease causes because of chemical factors such as medicine (as benzolism), and partly cause is not clear.Particularly in the therapeutic process of many tumor diseases, need to use chemotherapy or actinotherapy treatment mostly, these two kinds of therapies all can be killed and wounded human leukocytes in a large number, it is the important pathogenesis of primary disease, many tumour patients often can not continue to accept chemotherapy or radiotherapy because of leukopenia causes, so that lose the therapy apparatus meeting, cause the development and the deterioration of tumor.Therefore, the treatment primary disease is particularly treated the leukopenia problem in tumour patient radiotherapy, the chemotherapy process, becomes the key subjects of domestic and international medical circle.
Though modern medicine has had deep understanding for the cause of disease, but in treatment, still lack new means, Therapeutic Method does not have major progress in recent years, generally adopts group vitamins leukocyte increasing (as adenine phosphate), colony stimulating factor and use adrenocortical hormone to reduce the leukocyte that causes because of immunity to destroy.These therapies, curative effect is unsatisfactory, and with some serious adverse comparatively, has limited the clinical scope of application.
The traditional Chinese medical herbal treatment primary disease, general employing determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, vigorate qi and replenish the blood, grow methods such as anti-tonifying YANG, though some patient is had curative effect preferably, but it is cumbersome with decocting for Chinese herbal medicine, dose is excessive and the time is long, how can influence disadvantages such as appetite, it is very few that the clinical application that has limited tumour patient serves as based on the leukocyte increasing of Chinese medicine to raise variety in the existing market of Chinese medicine preparation of main effect, and generally be compound preparation, and flavour of a drug are many, curative effect is extensively and not special, and especially the effect of leukocyte increasing is slowly and not remarkable.
The objective of the invention is to, the medicine that provides a kind of Chinese medicine and western medicine to unite use, Chinese medicine and Western medicine can be brought into play synergism, reduce the side effect of Western medicine on the one hand, onset rapidly on the other hand.This medicine can be used for various acute and chronic leukopenias or agranulocytosis, is particularly useful for because of the above-mentioned disease due to tumor disease radiotherapy or the chemotherapy.In leukocyte increasing, there is not the toxic and side effects of other similar Western medicine, it is also few that degradation reacts under the appetite due to other Chinese medicine because of taking.
Summary of the invention
This invention compositions realizes as follows: by weight
94 parts of 1 part of Chinese medicine extract of lithium carbonate
Wherein Chinese medicine extract prepares according to the method for putting down in writing in the Chinese patent CN1058908A description: 0.15 part of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soaked in the molten device 7-10 hour.Decoct with water respectively then three times, time was respectively 1.5,1,0.5 hours, three fried liquid are merged, slow fire be concentrated into 1: 1 (g: ml) elimination insoluble matter, add 95% ethanol to pure content 80%, left standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the medicine of preparation promotion leucocyte hyperplasia.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has the effect that promotes leucocyte hyperplasia more by force, i.e. leukogenic effect.
Cyclophosphamide 120mg/kg/ day is injected in healthy Kunming mouse abdominal cavity continuously, continuous three days, treat that peripheral blood kind leukocyte reduces to 1000/mm
3After, begin to take and respectively organize medicine, set up leukopenia model after the mice chemotherapy, carry out the pharmacodynamics test that Pharmaceutical composition of the present invention promotes leucocyte hyperplasia.Each is organized medicine and used 7 days continuously, irritates stomach every day 1 time, 10 of every group of mices.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 0.94g/kg body weight as indicated above
3 lithium carbonate group: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight lithium carbonate+extractum 0.94g/kg body weight mentioned above is irritated stomach.
| Group | The leukocyte number |
| Group 1 | 1015±108.1/mm 3 |
| Group 2 | 1938±112.0/mm 3 |
| Group 3 | 2211±184.3/mm 3 |
| Group 4 | 3051±196.1/mm 3 |
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, lithium carbonate group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and lithium carbonate group.Show that there are cooperative effect in lithium carbonate and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Wherein compositions is made up of with weight ratio lithium carbonate and Chinese medicine extract mentioned above at 1: 94.
Can produce the capsule that contains following component in a conventional manner:
Wherein compositions is made up of with weight ratio lithium carbonate and Chinese medicine extract mentioned above at 1: 94.
Claims (3)
1. compositions that promotes leucocyte hyperplasia, it comprises by weight
94 parts of 1 part of Chinese medicine extract of lithium carbonate
Wherein Chinese medicine extract prepares according to following method: 0.15 part of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soak 7-10 hour in the container, decoct with water respectively then three times, the time was respectively 1.5,1,0.5 hours, and three fried liquid are merged, slow fire concentrates, the elimination insoluble matter adds 95% ethanol to pure content 80%, leaves standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
2. preparation of compositions method that promotes leucocyte hyperplasia, it is characterized in that: it comprises by weight
94 parts of 1 part of Chinese medicine extract of lithium carbonate
Wherein Chinese medicine extract prepares according to following method: 0.15 part of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soak 7-10 hour in the container, decoct with water respectively then three times, the time was respectively 1.5,1,0.5 hours, and three fried liquid are merged, slow fire concentrates, the elimination insoluble matter adds 95% ethanol to pure content 80%, leaves standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
3. the purposes of compositions as claimed in claim 1 in the medicine of preparation promotion leucocyte hyperplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101279945A CN101780142B (en) | 2010-03-17 | 2010-03-17 | Leukogenic medicament containing lithium carbonate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101279945A CN101780142B (en) | 2010-03-17 | 2010-03-17 | Leukogenic medicament containing lithium carbonate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101780142A CN101780142A (en) | 2010-07-21 |
| CN101780142B true CN101780142B (en) | 2011-09-14 |
Family
ID=42520366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101279945A Expired - Fee Related CN101780142B (en) | 2010-03-17 | 2010-03-17 | Leukogenic medicament containing lithium carbonate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101780142B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1058908A (en) * | 1990-08-15 | 1992-02-26 | 于宗亮 | Prescription of oral liquor for increasing leucocyte and manufacturing process |
| CN1911277A (en) * | 2006-09-01 | 2007-02-14 | 高熠 | Medicine for treating leukopenia |
| CN1927266A (en) * | 2006-09-01 | 2007-03-14 | 高熠 | Granulocyte raised drug comprising cepharanthine |
| CN101439088A (en) * | 2008-07-22 | 2009-05-27 | 罗丹晓 | Medicament for promoting leucocyte hyperplasia |
-
2010
- 2010-03-17 CN CN2010101279945A patent/CN101780142B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1058908A (en) * | 1990-08-15 | 1992-02-26 | 于宗亮 | Prescription of oral liquor for increasing leucocyte and manufacturing process |
| CN1911277A (en) * | 2006-09-01 | 2007-02-14 | 高熠 | Medicine for treating leukopenia |
| CN1927266A (en) * | 2006-09-01 | 2007-03-14 | 高熠 | Granulocyte raised drug comprising cepharanthine |
| CN101439088A (en) * | 2008-07-22 | 2009-05-27 | 罗丹晓 | Medicament for promoting leucocyte hyperplasia |
Non-Patent Citations (1)
| Title |
|---|
| 楼永义.碳酸锉治疗白细胞下降疾患中的体会.《浙江医学情报》.1995,(第3期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101780142A (en) | 2010-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN101062146A (en) | Chinese traditional medicine for treating gastric cancer and bone cancer | |
| CN100425252C (en) | Medicine for treating leukopenia | |
| CN101773545B (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN101439088B (en) | Medicament for promoting leucocyte hyperplasia | |
| CN101721471B (en) | Leucocyte-raising medicine containing leucogen | |
| CN100443092C (en) | Granulocyte raised drug comprising cepharanthine | |
| CN100441205C (en) | Medicine for treating blood system disease | |
| CN101780142B (en) | Leukogenic medicament containing lithium carbonate | |
| CN101773660B (en) | Medicament containing anubi-polypeotide | |
| CN103223149A (en) | Chinese herb medicine composition for treating lung cancer | |
| CN101439089B (en) | Medicament containing oxymatrine | |
| CN102225155B (en) | Medicament composition for treating pulmonary fibrosis | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN102008539B (en) | Medicinal composition for treating diseases such as viral myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN101559196B (en) | Medicament for treating the hyperplasia of mammary glands and preparation method thereof | |
| CN106138697B (en) | Chinese medicinal composition for preventing complications and relieving side effects of radiotherapy and chemotherapy of tumor patients | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN103251751B (en) | Traditional Chinese medicine composition for treating primary dysmenorrheal and preparation method thereof | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN107551217B (en) | Formula of traditional Chinese medicine composition for treating chronic heart failure by promoting expression of sarcoplasmic reticulum calcium pump | |
| CN102727606B (en) | Traditional Chinese medicinal pain-relieving plaster | |
| CN116688001A (en) | Traditional Chinese medicine composition for preventing and treating tumor bone metastasis and reducing osteoporosis and/or toxic and side effects of chemotherapy, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NINGBO YINZHOU CHANGDA BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHANG DAYU Effective date: 20110722 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Qian Xin Inventor after: Zhang Dayu Inventor before: Zhang Dayu |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG DAYU TO: QIAN XIN ZHANG DAYU Free format text: CORRECT: ADDRESS; FROM: 100070 BUILDING 18, AREA 8, HEADQUARTERS BASE, NO. 188, SOUTH 4TH RING ROADWEST, FENGTAI DISTRICT, BEIJING TO: 315104 ROOM 450, NO. 2, NO. 1, BUILDING 1, ZHAOYANGHUI, XIAYING SUBDISTRICT, YINZHOU DISTRICT, NINGBO CITY, ZHEJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110722 Address after: 315104 Zhejiang city of Ningbo province Yinzhou District streets under the Chaoyang 1 Hui building 1, room 450 No. 2 Applicant after: Jinzhou Aosheng Biotechnology Co., Ltd. Address before: 100070, No. 18, building eight, 188, base station, South Fourth Ring Road West, Beijing, Fengtai District Applicant before: Zhang Dayu |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HUAKE INTELLECTUAL PROPERTY SERVICE CO., L Free format text: FORMER OWNER: NINGBO YINZHOU CHANGDA BIOTECHNOLOGY CO., LTD. Effective date: 20130107 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 315104 NINGBO, ZHEJIANG PROVINCE TO: 226600 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130107 Address after: 226600 No. 8 Yingbin Road, Chengdong Town, Haian County, Nantong, Jiangsu Patentee after: Nantong Huake Intellectual Property Service Co.,Ltd. Address before: 315104 Zhejiang city of Ningbo province Yinzhou District streets under the Chaoyang 1 Hui building 1, room 450 No. 2 Patentee before: Jinzhou Aosheng Biotechnology Co., Ltd. |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 Termination date: 20130317 |